Evidence map›Paper›PMID 33113551›Full record

SynthesisBlood2020

Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients.

Abi Vijenthira, Inna Y Gong, Thomas A Fox, Stephen Booth, Gordon Cook, Bruno Fattizzo, Fernando Martín-Moro, Jerome Razanamahery, John C Riches, Jeff Zwicker and 9 more

Open access · bronzeAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Blood, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 394 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
394citing papers in PubMed, 8 pooled it
42.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

394 citing papers in PubMed, 8 syntheses or guidelines pooled it, 652 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Teclistamab in Relapsed or Refractory Multiple Myeloma.The New England journal of medicine · 2022
    Trial
  14. Article
  15. Article
  16. Review
  17. Article
  18. Observational
  19. Article
  20. Article

334 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 16 institutions in 8 countries.

Abi VijenthiraDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.
Inna Y GongDepartment of Medicine, University of Toronto, Toronto, ON, Canada.
Thomas A FoxDepartment of Haematology, University College London Hospital, London, United Kingdom.
Stephen BoothDepartment of Oncology, University of Oxford, Oxford, United Kingdom.
Gordon CookLeeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom.
Bruno FattizzoDepartment of Oncology and Onco-Hematology, University of Milan, Milan, Italy.
Fernando Martín-MoroDepartment of Hematology, Ramón y Cajal University Hospital, Madrid, Spain.
Jerome RazanamaheryDepartment of Internal Medicine, Besançon University Hospital, Besançon, France.
John C RichesCentre for Hemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
Jeff ZwickerBeth Israel Deaconess Medical Center, Boston, MA.
Rushad PatellBeth Israel Deaconess Medical Center, Boston, MA.
Marie Christiane VekemansDepartment of Hematology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain (UCLouvain), Brussels, Belgium.
Lydia ScarfòStrategic Research Program on CLL, Università Vita Salute and IRCCS Ospedale San Raffaele, Milan, Italy.
Thomas ChatzikonstantinouHCT Unit, Hematology Department, G. Papanicolaou Hospital, Thessaloniki, Greece.
Halil YildizDepartment of Internal Medicine and Infectious Diseases, Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium.
Raphaël LattenistDepartment of Internal Medicine and Infectious Diseases, Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium.
Ioannis MantzarisDepartment of Oncology, Montefiore Medical Center, Bronx, NY.
William A WoodDivision of Hematology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC; and.
Lisa K HicksDepartment of Medicine, University of Toronto, Toronto, ON, Canada.
Cliniques Universitaires Saint-Luc · BEBeth Israel Deaconess Medical Center · USCentre Hospitalier Universitaire de Besançon · FRG. Papanikolaou General Hospital · GRInstituto Cajal · ESIRCCS Ospedale San Raffaele · ITMontefiore Medical Center · USPrincess Margaret Cancer Centre · CAQueen Mary University of London · GBSt. Michael's Hospital · CAUniversity College Hospital · GBUniversity of Leeds · GBUniversity of Milan · ITUniversity of North Carolina at Chapel Hill · USUniversity of Oxford · GBUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Outcomes for patients with hematologic malignancy infected with COVID-19 have not been aggregated. The objective of this study was to perform a systematic review and meta-analysis to estimate the risk of death and other important outcomes for these patients. We searched PubMed and EMBASE up to 20 August 2020 to identify reports of patients with hematologic malignancy and COVID-19. The primary outcome was a pooled mortality estimate, considering all patients and only hospitalized patients. Secondary outcomes included risk of intensive care unit admission and ventilation in hospitalized patients. Subgroup analyses included mortality stratified by age, treatment status, and malignancy subtype. Pooled prevalence, risk ratios (RRs), and 95% confidence intervals (CIs) were calculated using a random-effects model. Thirty-four adult and 5 pediatric studies (3377 patients) from Asia, Europe, and North America were included (14 of 34 adult studies included only hospitalized patients). Risk of death among adult patients was 34% (95% CI, 28-39; N = 3240) in this sample of predominantly hospitalized patients. Patients aged ≥60 years had a significantly higher risk of death than patients <60 years (RR, 1.82; 95% CI, 1.45-2.27; N = 1169). The risk of death in pediatric patients was 4% (95% CI, 1-9; N = 102). RR of death comparing patients with recent systemic anticancer therapy to no treatment was 1.17 (95% CI, 0.83-1.64; N = 736). Adult patients with hematologic malignancy and COVID-19, especially hospitalized patients, have a high risk of dying. Patients ≥60 years have significantly higher mortality; pediatric patients appear to be relatively spared. Recent cancer treatment does not appear to significantly increase the risk of death.

Indexed as

COVID-19Hematologic NeoplasmsHospitalizationHumansIntensive Care UnitsPrognosisSARS-CoV-2Survival Rate

Identifiers

PMID33113551
PMCPMC7746126
OpenAlexW3097738396

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.